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Purpose: To report the 5-year follow-up results of a randomized controlled trial   
comparing bipolar transurethral resection of the prostate (TURP) with standard 
monopolar TURP for the treatment of benign prostatic obstruction (BPO). Materi-
als and Methods: A total of 220 patients were randomized to bipolar plasmakinet-
ic TURP (PK-TURP) or monopolar TURP (M-TURP). Catheterization time was 
the primary endpoint of this study. Secondary outcomes included operation time, 
hospital stay, as well as decline in postoperative serum sodium and hemoglobin lev-
els. All patients were assessed preoperatively and followed-up at 1, 6, 12, 24, 36, 
48, and 60 months postoperatively. Parameters assessed included quality of life, 
transrectal ultrasound, serum prostate-specific antigen level, postvoid residual urine   
volume, maximum urinary flow rates (Qmax), and International Prostate Symptom 
Score. Patient baseline characteristics, perioperative data including complications, 
and postoperative outcomes were compared. Complication occurrence was graded 
according to the modified Clavien classification system. Results: PK-TURP was 
significantly superior to M-TURP in terms of operation time, intraoperative irriga-
tion volume, resected tissue weight, decreases in hemoglobin and sodium, postop-
erative irrigation volume and time, catheterization time, and hospital stay. At 5 
years postoperatively, efficacy was comparable between arms. No differences were 
detected in safety outcomes except that the clot retention rate was significantly 
greater after M-TURP. Conclusion: Our results indicate that PK-TURP is equally 
as effective in the treatment of BPO, but has a more favorable safety profile in com-
parison to M-TURP. The clinical efficacy of PK-TURP is long-lasting and compa-
rable with M-TURP.
Key Words:    Randomized controlled trial, bipolar plasmakinetic, transurethral re-
section of the prostate, follow-up
INTRODUCTION
         
Benign prostatic obstruction (BPO) is one of the most common diseases in elderly 
men. The goals of therapy are to improve quality of life, reduce symptoms, ensure RCT Comparing Bipolar PK-TURP and M-TURP of the Prostate
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prostate-specific antigen (PSA) level.
A total of 220 cases were enrolled in the study. Random-
ization was performed using the opaque envelope method, 
which resulted in 110 patients in each group. The study was 
approved by our institution’s ethics committee, and informed 
consent was obtained from all patients recruited. Neither 
the patient nor the surgeon was blinded to the type of the 
procedure performed. One independent investigator, who 
was blinded to the type of surgery, performed the 1-, 6-, 
12-, 24-, 36-, 48-, and 60-month follow-ups. Perioperative 
outcome measures included the need for blood transfusion, 
operation time, resected tissue weight, changes in serum so-
dium and hemoglobin levels, intraoperative and postopera-
tive irrigation, hospitalization, TUR syndrome, and dura-
tion of catheterization. And postoperative outcome measures 
included Qmax, PSA level IPSS, postvoid residual urine (PVR) 
volume, and quality of life (QoL) scores, at each follow-up 
visit. Catheterization time was the primary endpoint of this 
study. Secondary outcomes included operation time, hospi-
tal stay, and decline in postoperative serum sodium and he-
moglobin levels. All perioperative and postoperative adverse 
events were recorded, and all parameters were compared at 
baseline and at each postoperative visit between the two 
study arms. Complications were graded according to the 
modified Clavien classification system as previously pro-
posed for TURP procedures.7,8
Surgical procedures
All patients received epidural anesthesia as well as 400 mg 
of ciprofloxacin administered intravenously. All procedures 
were performed by a single senior surgeon with extensive 
experience in TURP procedures. All patients were treated 
similarly, apart from the intervention. Conventional M-TURP 
was performed with a 24F resectoscope (Olympus, Ham-
burg, Germany) and a loop electrode for TURP (5 mm di-
ameter, Olympus), using an UES-30 generator (Olympus) 
set at 110 W (cutting mode) and 70 W (coagulation mode). 
Glycine 1.5% was used as irrigation fluid. Bipolar resection 
was performed with a 24F resectoscope (Gyrus Medical 
Ltd., Cardiff, UK) and a plasma-loop electrode (5 mm di-
ameter, Gyrus Medical Ltd.), using a Gyrus Plasmakinetic 
generator (Gyrus Medical Ltd.) set at 160 W (cutting mode) 
and 80 W (coagulation mode). All the prostatic chips were 
removed from the bladder at the end of the procedure. Sub-
sequently, we inserted a 22F three-way Foley catheter into 
bladder and initiated irrigate the bladder with normal saline 
solution in the operating room. At least within 10 min after 
safety, and minimize side effects.1 Transurethral resection 
of the prostate (TURP) is considered to be the surgical gold 
standard for BPO, because of its well documented long-term 
efficacy.2 However, TURP complications such as bleeding, 
transurethral resection (TUR) syndrome, infection, urethral 
stricture, and incontinence still occur.3 A prospective multi-
center study on 10654 patients with BPO treated with TURP 
showed that mortality has decreased (0.1%), while morbidi-
ty, although reduced, remains high (11.1%).4 In order to min-
imize the perioperative morbidity of TURP, various mini-
mally invasive alternatives have been introduced. The most 
significant, recent improvement of TURP was the incorpo-
ration of bipolar technology. Bipolar TURP addresses the 
main drawback of monopolar TURP (M-TURP) by allow-
ing the procedure to be performed in a normal saline envi-
ronment,5 and, as a result, bipolar TURP seems to be quite 
promising.5,6
The aim of this study was to compare the durability safe-
ty, and efficacy of bipolar plasmakinetic (PK) TURP with 
that of standard M-TURP in a randomized controlled trial 
(RCT) of 220 patients with BPO. We report the results of 
the 5-year follow-up for the first time after the initiation of 
the trial. To our knowledge, the 5-year follow-up of these 
patients represents the longest studied follow-up of the bi-
polar TURP procedure to date.
MATERIALS AND METHODS
　　　
Patients
From January 2003 to October 2005, patients with BPO in 
our Department of Urology were invited to participate in 
the trial. Inclusion criteria included maximal urinary flow 
rate (Qmax) of less than 15 mL/s, age greater than 45 years, 
prostate volume on transrectal ultrasound exceeding 20 g 
with no upper limit, medication (5α-reductase inhibitors or 
α-blockers) failure, and International Prostate Symptom 
Score (IPSS) of greater than 12. The use of medications such 
as 5α-reductase inhibitors or α-blockers was stopped within 
the last 3 months or 2 weeks before surgery, respectively. Pa-
tients with known renal impairment, neurovesical dysfunc-
tion, bladder calculus, prostate carcinoma, a previous history 
of prostatic or urethral surgery, urethral stricture, and associ-
ated hydronephrosis were excluded. Urodynamic investiga-
tion was not used routinely in this trial. A transrectal prostate 
biopsy was performed in patients upon suspicion of prostat-
ic malignancy on digital rectal examination and/or elevated Chang-Ying Xie, et al.
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cal analysis was based on the principles of intention to treat 
and performed using SPSS software version 17.0. Statistical 
significance was considered at p<0.05 for all analyses.
 
RESULTS
 
Baseline patient characteristics were comparable between 
arms (Table 1). All patients’ histologic finding were benign 
prostatic hyperplasia. Seventy percent of the patients com-
pleted the 5-year follow-up: 78 and 79 out of 110 in the 
PK- and M-TURP arms, respectively. Reasons for drop out 
included death from other causes (13 patients), address 
changed (24 patients), and unwillingness to follow-up due 
to complications (26 patients). Causes of death were shown 
in Table 2. Significant differences favoring PK-TURP were 
detected in all perioperative parameters (Table 3). 
Changes in urodynamic and symptoms parameters
In both groups, significant improvements in QoL, Qmax, 
PVR volume, and IPSS were noted at 5 years of follow-up 
(Table 4).
Complications
In each arm, eight patients were diagnosed with urinary 
tract infection (UTI), because these patients’ urine cultures 
were positive. After the sensitive antibiotics were used for 3 
to 6 days, these patients’ irritative symptoms eased. After 
catheter removal, in the M-TURP arm, two patients were 
diagnosed with acute urine retention. Clot retention was ob-
served in 1 patient in the PK-TURP group and in 8 patients 
in the M-TURP group (p=0.041). Hematuria occurred post-
operatively in 4 patients in the M-TURP arm and in 2 pa-
the end of the operation, we measured the level of patients’ 
serum sodium and hemoglobin again. Once the patient was 
able to drink an adequate amount of fiuid for auto-irriga-
tion, saline irrigation was stopped. At last, we removed the 
catheter, if the urine of the patient’s was completely clear, 
and the patient had passed stool. 
Statistical analysis
Assuming a two-sided significance test with the significance 
level of α=0.05 for the current study, with our sample size of 
110 cases per group, the estimated power was 95%. Contin-
uous variables were tested for normality and equality of 
variances using the Kolmogorov-Smirnov-test and the Lev-
ene F-test, respectively. Baseline characteristics (apart from 
perioperative hemoglobin levels), postoperative data and 
perioperative data between the two groups were compared 
by means of the Mann-Whitney U-test. Perioperative he-
moglobin levels were analyzed using a t-test. Postoperative 
adverse events were compared by means of Pearson chi-
squared test with continuity correction or Fisher’s exact test. 
The one-way ANOVA model was used to compare preopera-
tive and postoperative parameters within each group. Statisti-
Table 2. Cause of Death in Each Group
Cause M-TURP 
group
PK-TURP 
group
Cerebrovascular accident 3 2
Hepatoma 2
Pulmonary carcinoma 2
Myocardial infarction﹡ 1
Traffic accident 1 2
M, monopolar; PK, plasmakinetic; TURP, transurethral resection of the 
prostate. 
﹡One patient was diagnosed with myocardial infarction at 2 years postop-
eratively.  
Table 1. Patient Characteristics
Parameters
M-TURP group PK-TURP group
p value 95% CI of the difference
Mean±SD   Mean±SD  
Age (yrs)      64.91±10.92      69.95±11.54   0.489 (63.94, 66.92)
TRUS prostate volume (mL)     67.00±18.93      65.86±17.32  0.828 (64.04, 68.82)
Serum PSA (mg/mL)      1.41±1.34      1.39±1.35  0.764 (-0.36, 3.16)
IPSS   22.75±5.59    23.78±5.62  0.091 (22.52, 24.00)
QoL score     4.44±1.10      4.48±0.81  0.789 (3.19, 5.73)
Hemoglobin (g/dL)  13.58 ±0.91   13.76±0.92 0.156 (12.45, 14.89)
Serum sodium (mmol/L) 138.98±3.29  138.43±3.22  0.237 (138.27, 138.92)
Qmax (mL/s)     9.65±2.57      9.86±2.70  0.557 (9.41, 10.11)
PVR volume (mL)     96.35±25.58       94.51±26.73  0.477 (91.98, 98.88)
M, monopolar; PK, plasmakinetic; TURP, transurethral resection of the prostate; SD, standard deviation; CI, conﬁdence interval; TRUS, transrectal ultra-
sound; PSA, prostate-speciﬁc antigen; IPSS, International Prostate Symptom Score; QoL, quality of life; Qmax, maximal urinary ﬂow rate; PVR, postvoid 
residual urine. RCT Comparing Bipolar PK-TURP and M-TURP of the Prostate
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Table 3. Perioperative Data of the Patients in Each Group
Parameters
M-TURP group PK-TURP group
p value 95% CI of the difference
Mean±SD   Mean±SD  
Operative time, min   60.01±20.06      55.03±16.30    0.033 (55.09, 59.95)
Intraoperative irrigation volume (L) 12.70±3.74    11.75±2.92    0.026 (11.77, 12.69)
Resected tissue weight (g)   52.23±12.84      55.39±17.79    0.014 (52.05, 55.57)
Decrease in hemoglobin (g/dL)   1.58±0.65      1.22±0.54    0.014 (0.58, 2.22)
Decrease in sodium (mmol/L)   2.03±1.35      1.62±1.31    0.014 (1.65, 2.01)
Catheter duration (days)   3.61±1.15      2.70±0.80  <0.001 (3.02, 3.30)
Hospital stay (days)   5.19±1.17      4.18±0.89  <0.001 (3.16, 6.22)
Postoperative irrigation volume (L) 22.38±7.34    13.47±4.75  <0.001 (11.77, 12.67)
Postoperative irrigation time 
  (hrs) 24.45±8.37    15.84±4.85  <0.001 (19.10, 21.22)
M, monopolar; PK, plasmakinetic; TURP, transurethral resection of the prostate; SD, standard deviation; CI, conﬁdence interval.
Table 4. Efficacy of Bipolar vs. Monopolar TURP
Parameters
M-TURP PK-TURP
p value 95% CI of the difference
Mean±SD   Mean±SD 
IPSS
    1 yr    6.79±2.59﹡   6.50±2.03﹡ <0.001 (6.44, 7.06)
    2 yrs    6.79±2.56﹡   5.48±1.67﹡ <0.001 (5.82, 6.11)
    3 yrs    6.49±2.44﹡   4.84±1.42﹡ <0.001 (5.34, 5.96)
    4 yrs    6.11±2.27﹡   6.91±2.03﹡   0.002 (6.18, 6.84)
    5 yrs    6.58±2.43﹡    7.20±1.65﹡    0.194 (6.56, 7.22)
QoL scores  
    1 yr    2.56±0.97﹡    2.15±0.58﹡ <0.001 (2.23, 2.47)
    2 yrs    1.84±0.75﹡   1.40±0.57﹡  <0.001 (1.52, 1.72)
    3 yrs    1.60±0.60﹡   1.27±0.52﹡  <0.001 (1.35, 1.51)
    4 yrs    1.88±0.75﹡    1.63±0.68﹡   0.034 (1.63, 1.87)
    5 yrs    1.99±0.61﹡    1.82±0.64﹡   0.097 (0.92, 2.88)
Qmax (mL/s)
    1 yr  27.37±8.91﹡  28.05±8.69﹡   0.597 (26.50, 28.90)
    2 yrs  28.53±8.31﹡ 29.67±8.09﹡    0.436 (27.95, 30.27)
    3 yrs  28.81±7.91﹡  30.80±7.65﹡    0.118 (28.68, 30.96)
    4 yrs  27.83±7.02﹡  39.91±7.17﹡    0.058 (27.81, 29.97)
    5 yrs  24.94±5.80﹡  26.41±5.22﹡   0.125 (24.82, 26.54)
PVR volume (mL)  
    1 yr    16.20±10.89﹡  12.02±7.49﹡    0.004 (12.79, 15.41)
    2 yrs  11.24±7.68﹡    7.51±3.71﹡    0.001 (8.47, 10.23)
    3 yrs    7.61±3.81﹡    6.51±2.51﹡    0.010 (6.58, 7.52)
    4 yrs 10.18 ±6.39﹡    7.98±2.52﹡    0.215 (8.32, 9.80)
    5 yrs  14.44±8.31﹡  11.72±4.85﹡    0.176 (11.99, 14.15)
Serum PSA (ng/mL)  
    1 yr    0.49±0.56﹡   0.37±0.42﹡    0.276 (0.37, 0.46)
    2 yrs    0.34±0.43﹡   0.30±0.38﹡    0.127 (0.26, 0.38)
    3 yrs    0.31±0.42﹡   0.24±0.31﹡    0.091 (0.22, 0.34)
    4 yrs    0.34±0.27﹡    0.31±0.27﹡    0.325 (-0.02, 0.06)
    5 yrs    0.43±0.53﹡    0.30±0.30﹡    0.705 (0.30, 0.42)
M, monopolar; PK, plasmakinetic; TURP, transurethral resection of the prostate; SD, standard deviation; CI, conﬁdence interval; IPSS, International Prostate 
Symptom Score; QoL, quality of life; Qmax, maximum urinary ﬂow rate; PVR, postvoid residual urine; PSA, prostate-speciﬁc antigen.  
﹡p<0.001, compared to the perioperative value.Chang-Ying Xie, et al.
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group and in 4 patients (3.6%) in the PK-TURP group 
(p=0.373). In both arms, midterm complications were simi-
lar (Table 5). In each arm, 4 patients were diagnosed with 
urethral strictures. These patients were required dilatation in 
tients in the PK-TURP group (p=0.679). Furthermore, due 
to postoperative hematuria, blood transfusion was neces-
sary in 2 patients in the M-TURP arm (p=0.477). Bladder 
neck stricture occurred in 8 patients (7.3%) in the M-TURP 
Table 5.  Complications in Each Group
Number of patients
M-TURP group PK-TURP group
p value
110 110
Early (%)
    AUR 2 (1.8) 0 0.477
    Clot retention 8 (7.3) 1 (0.9) 0.041
    Hematuria 4 (3.6) 2 (1.8) 0.679
    Urinary tract infection  8 (7.3) 8 (7.3) 1
    TUR syndrome﹡ 2 (1.8) 0 0.477
    Blood transfusion 2 (1.8) 0 0.477
Long term (%)
    Urethral stricture 4 (3.6) 4 (3.6) 1
    Bladder neck stenosis 8 (7.3) 4 (3.6) 0.373
    Reoperation 
        1 yr 1 0
        2 yrs 2 1
        3 yrs 4 2
        4 yrs 3 2
        5 yrs 1 2
    BPH recurrence (%) 3 (2.7) 3 (2.7) 1
M, monopolar; PK, plasmakinetic; TURP, transurethral resection of the prostate; AUR, acute urine retention; TUR, transurethral resection; BPH, benign 
prostatic hyperplasia.
﹡Two patients developed TUR syndrome at 7 and 11 h after surgery, with sodium levels of 117 and 121 mmol/L, respectively.
Table 6. Complications during the Postoperative Period Classified according to the Modified Clavien System
Grade
Number of complications
Complication Management
M-TURP PK-TURP
I 2 0 AUR Bedside recatheterization
2 2 Hematuria
Bedside bladder irrigation  
  (prolonged)±clot evacuation 
                      ±catheter traction
8 1 Clot retention
Bedside clot evacuation via  
  catheter±catheter change 
               ±bladder irrigation
  4 4 Urethral stricture Dilation
Rate (%) 16/36 (44.4) 7/19 (36.8)
p value 0.401
II 8 8 Urinary tract infection Antibiotics
2 0 Hematuria Transfusion
Rate (%) 10/36 (27.8) 8/19 (42.1)
p value 0.218
IIIb 8 4 Bladder neck stenosis Bladder neck incision
Rate (%) 8/36 (22.2) 4/19 (21.1)
p value 0.603
IVb 2 0 TUR syndrome Admission to ICU
Rate (%) 2/36 (5.6) 0/19 (0)
p value 0.424
M, monopolar; PK, plasmakinetic; TURP, transurethral resection of the prostate; AUR, acute urine retention; TUR, transurethral resection; ICU, intensive 
care unit.RCT Comparing Bipolar PK-TURP and M-TURP of the Prostate
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bin was significantly higher in the M-TURP group than in 
the PK-TURP group. These findings are also in agreement 
with the two recent RCTs of Chen, et al.19 and Fagerström, 
et al.20 The authors concluded that bipolar TURP reduced 
overall perioperative and total surgical bleeding by 34%.20 
These results, however, did not translate into significant dif-
ferences in blood transfusion rates. Although none of the 
patients (0%) in the PK-TURP arm required blood transfu-
sions, these occurred in 2 patients (1.8%) in the M-TURP 
arm due to a postoperative hematuria. These excellent hae-
mostatic characteristics resulted in significantly less periop-
erative bladder irrigation, as well as shorter catheter dura-
tion and hospital stay for PK-TURP patients. 
The present study’s demonstration of a statistically signifi-
cant decrease of serum sodium between the two resection 
techniques was confirmed in two other studies.19,21 TUR syn-
drome was detected in two of the M-TURP patients (1.8%), 
while none of the PK-TURP group patients (0%) devel-
oped TUR syndrome. These results did not translate into 
significant differences in TUR syndrome rates, however, as 
previously reported in individual RCTs.6,8,21 Nevertheless, 
these results suggest that PK-TURP eliminates the danger 
of TUR syndrome by using normal saline as an irrigation 
fluid, thus making it a safer choice for patients with heart 
disease. Mamoulakis, et al.6 concluded in their very detailed 
meta-analysis that their results provided strong evidence to 
support the notion that ‘‘with B-TURP, dilutional hypona-
tremia of TUR syndrome is a historical event in the 21st 
century’’.22 However, Rassweiler, et al.23 indicated bipolar 
technology does not prevent fluid absorption, which re-
mains possible and should always be kept in mind.
In addition to the advantages mentioned above, bipolar 
TURP also allows for more rapid catheter removal and a 
shorter hospital stay. Recently, Ahyai, et al.9 reported in their 
meta-analysis that the length of catheter time (mean: 2.7 d) 
after bipolar TURP was slightly shorter compared to monop-
olar TURP. Similarly, in our study, the mean catheterization 
time in PK-TURP patients was shorter than that in the M-
TURP patients (2.70±0.80 d vs. 3.61±1.15 d). Consequently, 
the average hospital stay was also shorter in the PK-TURP 
group compared with the M-TURP group (4.18±0.89 d vs. 
5.19±1.17 d).
TURP is associated with proven durability of improved 
micturition. According to the analysis of Ahyai, et al.9 in 
their recent review, TURP resulted in a substantial improve-
ment of mean Qmax (+162%) and a significant reduction of 
mean IPSS (-70%), mean QoL scores (-69%), and mean 
the office without internal urethrotomies.
Reoperations due to late complications consisted of blad-
der neck stricture (n=12), a second PK-TURP (n=3), and a 
second M-TURP (n=3). Specific complication rates and 
their grading based on the modified Clavien classification 
system are shown in Table 5 and 6. No differences were de-
tected in Clavien grade between arms.
DISCUSSION
BPO can be managed by medical treatments or surgical 
procedures. TURP, developed in 1920s, is considered the 
cornerstone of surgical management for BPO, due to the 
procedure’s outstanding, well-documented, long-term treat-
ment efficacy.2 Meanwhile, the associated morbidity of 
TURP has been reported to be as high as 11.1%.4 The UTI 
rate is 3.6%, TUR syndrome is found in 1.4% of patients, 
and blood transfusion is required by 2.9% of patients.4 Fur-
thermore, the urethral stricture rate is 2.2 to 9.8% and 0.3 to 
9.2% of patients may have bladder neck stricture in the lon-
ger term.3 After five years, the retreatment rate range is 3 to 
14.5%.3
The bipolar TURP system appears promising in regards 
to minimizing the morbidity of standard monopolar TURP. 
The fact that bipolar shares durable in time with monopolar 
TURP, similar clinical efficacy with low long-term compli-
cation rates, which has already confirmed by previous re-
view and meta-analysis.5,6,9-11 Several prior RCT studies12-15 
have reported improvements in both flow rates and symp-
toms with minimal complications. But, these latter studies 
were limited by a short-term follow-up (1 year)12-14 or a mod-
est sample size.15 We report 5-year follow-up data from a 
RCT comparing M-TURP and PK-TURP in a relatively large 
sample size. To our knowledge, this effort represents the 
longest follow-up on bipolar TURP.
The degree of bleeding is less with bipolar TURP, because 
plasma can create the cut and seal effect.16 In a previous 
study, intraoperative monopolar coagulation zones were re-
ported to be lower than bipolar ones, signifying that the he-
mostatic efficacy of bipolar TURP might be better.17 Previous 
RCTs comparing bipolar resection with M-TURP demon-
strated that blood loss was significantly less in the bipolar 
group.14,18 Nevertheless, in the recent meta-analysis of Ahyai, 
et al.,9 the risk of blood transfusion in both techniques was 
comparable, suggesting a similar blood loss for monopolar 
and bipolar TURP. In this study, the decrease in hemoglo-Chang-Ying Xie, et al.
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here was in agreement with the previously reported 3 to 
14.5% retreatment rate.3  
In conclusion, to the best of our knowledge, our study is 
the only RCT to compare PK-TURP with standard TURP 
that includes 5 years of follow-up data. Our results indicate 
that PK-TURP is as effective as M-TURP in the treatment 
of BPO with an improved safety profile. The clinical effica-
cy of PK-TURP was comparable to that of M-TURP during 
the 5-year follow-up. Future studies, including an even larg-
er number of patients and a longer follow-up period are 
necessary to reinforce the present findings. 
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